Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of VX-840 in Healthy Subjects
NCT05324410Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-840 in APOL1-mediated kidney disease (AMKD) (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Apr 2022; status: completed.
02
Drugs
VX-840
03
Conditions
APOL1-mediated kidney disease (AMKD)
Beyond the preview
Go deeper on NCT05324410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05324410.